Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.

Abstract: In a network switch of a software-defined network (SDN) architecture, a method for improving cache replacement (CR) efficiency implemented therein, the method comprising maintaining a flow table comprising a plurality of flow entries, computing a replacement index (RI) value for each of the plurality of flow entries resulting in a plurality of RI values, wherein computing an RI value for a flow entry is at least partially based on latency sensitivity of a forwarding path specified by the flow entry, and generating, based on at least some of the computed RI values, an eviction list comprising a number of list entries, wherein each of the list entries points to one of at least a fraction of the flow entries.

Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.

Abstract: The invention provides inhibitors of influenza endonuclease activity and tools for their discovery.

Abstract: The present disclosure is directed towards small modules, web plugins, which may be placed on any influential content which simplify and promote sales by operating as a social sales point (SSP). SSP's simplify sales by avoiding buyers engaging in any further searches or product comparisons. The sales process is promoted and supported by the inherent trust and revere placed upon the content owner, with the influential content providing a framework to complete the transaction and close the sale. Additionally, SSP promotes sales by keeping track of the reward of referrers, and provide a fair way of sharing reward with this social middle man. SSP allows simple proliferation, so that any effective promotion will quickly spread to its maximum by the power of social media.

Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF 30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.

Abstract: The efficiency of data de-duplication may be improved by storing related file data in a single container, or in multiple linked containers, of a history. Additionally, the efficiency of data de-duplication may be improved when shorter hash tables are used to reference historical data in a history. Shorter hash tables may be achieved by storing fewer than all the hash values obtained for a given amount of historical data. Further, the efficiency of data de-duplication may be improved by comparing related incoming file data with historical data from a container without hashing/chunking the remaining file data upon matching an earlier chunk of the incoming file data to the container.

Abstract: System and method embodiments are provided herein to test Network Attached Storage (NAS) server performance by generating a sufficient load in NAS client sessions. A test device is configured to run as many needed NAS clients to generate enough NAS session load for evaluating the NAS server performance. An embodiment comprises a method for testing a NAS server comprising starting a NAS client, establishing a session between the NAS client and the NAS server, exchanging communications for the session at a network stack layer below the NAS client, terminating the NAS client, starting a second NAS client, establishing a subsequent session between the second NAS client and the NAS server, exchanging communications for the subsequent session at the network stack layer while exchanging communications for the session, and terminating the second NAS client.

Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.

Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.

Abstract: The invention provides inhibitors of influenza endonuclease activity and tools for their discovery.

Abstract: The present invention provides engineered novel variants of human immunodeficiency virus reverse transcriptase (HIV-RT) capable of being expressed in large quantity and that with polymerase and RNase H activity in a form that facilitates crystallization and high resolution structure resolution following X-ray diffraction. The present invention facilitates high resolution determination of RT in complexes with RT drugs and RT inhibitors, and provides methods for systematic generation of variants and for structure based identification and design of novel RT inhibitors.

Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.

Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.

Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.

Abstract: The invention provides a target and methods for specific binding and inhibition of RlmA proteins from bacterial specie The invention is directed to a method for identifying compounds that bind to a bacterial RlmA-binding pocket, comprising preparing a reaction solution comprising the compound to tested and an entity comprising a bacterial RlmA-binding pocket and detecting presence or amount of binding. The invention has applications in control of bacterial gene expression, control bacterial growth, antibacterial chemistry, and antibacterial therapy.